Peptide Preclinical Licensing Benchmarks
Deal economics across 13 transactions with 9 disclosed upfront payments. Primary-source-verified from SEC EDGAR, FTC filings, and direct research.
Median Upfront
$70M
9 deals with terms
Median Total Value
$768M
Upfront + milestones
Royalty Range
4.4%--7%
Average low--high
Deal Count
13
2017--2026
The median upfront payment for preclinical peptide licensing deals is $70M, based on 9 deals with disclosed terms from 2017--2026. Total deal values (including milestones) reach a median of $768M. Royalty rates typically range from 4.4% to 7%. All data is primary-source-verified from SEC EDGAR, FTC pre-merger filings, and company press releases.
Representative Transactions
| Licensor | Licensee | Year | Upfront | Total Value |
|---|---|---|---|---|
| Gubra | AbbVie | 2025 | $350M | $2.2B |
| Ascendis Pharma | Novo Nordisk | 2018 | $285M | -- |
| Nimble Therapeutics | AbbVie | 2024 | $200M | $200M |
Showing 3 of 9 deals with disclosed terms. Full comp set available in the report.
Full Peptide Preclinical Comp Set
Get the complete analysis -- 9 deals with upfronts, milestones, royalties, and term structures.
Primary-source-verified from SEC EDGAR, FTC filings, and direct research
Run Your Own Analysis
Get a customized deal estimate for your specific peptide asset with our proprietary calculator.
Start CalculatingMethodology
This analysis draws from the Ambrosia Ventures proprietary deal database (1,600+ verified biopharma transactions, 2017--2026). All deal terms are primary-source-verified from SEC EDGAR (10-K, 10-Q, 8-K filings), FTC pre-merger notifications, FDA Orange Book, and company press releases. No secondary-source or scraped data is included. Medians are calculated from deals with disclosed financial terms only.